JP2012505154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505154A5 JP2012505154A5 JP2011517819A JP2011517819A JP2012505154A5 JP 2012505154 A5 JP2012505154 A5 JP 2012505154A5 JP 2011517819 A JP2011517819 A JP 2011517819A JP 2011517819 A JP2011517819 A JP 2011517819A JP 2012505154 A5 JP2012505154 A5 JP 2012505154A5
- Authority
- JP
- Japan
- Prior art keywords
- microglobulin
- alpha
- pharmaceutical composition
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101800001761 alpha-1-microglobulin Proteins 0.000 claims 10
- 102000003966 alpha-1-microglobulin Human genes 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 230000000875 corresponding Effects 0.000 claims 2
- 230000002255 enzymatic Effects 0.000 claims 2
- 101500020335 human Alpha-1-microglobulin Proteins 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 210000001124 Body Fluids Anatomy 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 108009000578 Oxidative Stress Proteins 0.000 claims 1
- 230000002292 Radical scavenging Effects 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002357 osmotic agent Substances 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- -1 pH adjusters Substances 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
Claims (13)
- 酵素的還元、非酵素的還元及びラジカル除去の組み合わせにより酸化的損傷を修復又は妨げることによる、酸化ストレスに関与する疾患又は状態の治療又は予防に用いるための、アルファ-1-ミクログロブリンと医薬的に許容され得る賦形剤とを含む医薬組成物。
- 前記疾患又は状態が、体の流体中の遊離ヘモグロビンの存在を伴う疾患又は状態である請求項１に記載の医薬組成物。
- アルファ-1-ミクログロブリンが、ヒトアルファ-1-ミクログロブリン(配列番号１)と少なくとも60%の同一性を有する請求項１又は２に記載の医薬組成物。
- アルファ-1-ミクログロブリンが、ヒトアルファ-1-ミクログロブリン(配列番号１)である請求項１〜３のいずれか１項に記載の医薬組成物。
- アルファ-1-ミクログロブリンが、ヒト組換えアルファ-1-ミクログロブリン(配列番号２)と少なくとも60%の同一性を有する請求項１〜４のいずれか１項に記載の医薬組成物。
- アルファ-1-ミクログロブリンが、ヒト組換えアルファ-1-ミクログロブリン(配列番号２)である請求項１〜３又は５のいずれか１項に記載の医薬組成物。
- アルファ-1-ミクログロブリンが、非経口投与される請求項１〜６のいずれか１項に記載の医薬組成物。
- アルファ-1-ミクログロブリンが、局所的に、体腔又は皮膚に投与される請求項１〜７のいずれか１項に記載の医薬組成物。
- 前記医薬的に許容され得る賦形剤が、溶媒、pH調整剤、浸透活性剤、共溶媒、可溶化剤、乳化剤、懸濁化剤、界面活性剤、および湿潤剤から選択される請求項１〜８のいずれか１項に記載の医薬組成物。
- 配列：5'-CCUAUGUGGUCCACACCAA-3' (配列番号５)により規定されるヌクレオチド配列と少なくとも60%の類似性を示す配列からなるヌクレオチド。
- 対応するDNA配列により規定される請求項10に記載のヌクレオチド。
- アルファ-1-ミクログロブリンの発現を発現停止するための、配列：5'-CCUAUGUGGUCCACACCAA-3' (配列番号５)により規定されるヌクレオチド配列からなるヌクレオチド。
- 対応するDNA配列により規定される請求項12に記載のヌクレオチド。
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13533808P | 2008-07-18 | 2008-07-18 | |
| US61/135,338 | 2008-07-18 | ||
| DKPA200801024 | 2008-07-18 | ||
| DKPA200801024 | 2008-07-18 | ||
| US18938108P | 2008-08-18 | 2008-08-18 | |
| DKPA200801116 | 2008-08-18 | ||
| DKPA200801116 | 2008-08-18 | ||
| US61/189,381 | 2008-08-18 | ||
| US19750608P | 2008-10-27 | 2008-10-27 | |
| DKPA200801478 | 2008-10-27 | ||
| US61/197,506 | 2008-10-27 | ||
| DKPA200801478 | 2008-10-27 | ||
| PCT/EP2009/005217 WO2010006809A2 (en) | 2008-07-18 | 2009-07-17 | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014236500A Division JP6406987B2 (ja) | 2008-07-18 | 2014-11-21 | ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505154A JP2012505154A (ja) | 2012-03-01 |
| JP2012505154A5 true JP2012505154A5 (ja) | 2012-09-06 |
| JP5694928B2 JP5694928B2 (ja) | 2015-04-01 |
Family
ID=41550762
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517819A Expired - Fee Related JP5694928B2 (ja) | 2008-07-18 | 2009-07-17 | ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用 |
| JP2014236500A Expired - Fee Related JP6406987B2 (ja) | 2008-07-18 | 2014-11-21 | ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用 |
| JP2015241096A Expired - Fee Related JP6175478B2 (ja) | 2008-07-18 | 2015-12-10 | ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014236500A Expired - Fee Related JP6406987B2 (ja) | 2008-07-18 | 2014-11-21 | ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用 |
| JP2015241096A Expired - Fee Related JP6175478B2 (ja) | 2008-07-18 | 2015-12-10 | ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10350268B2 (ja) |
| EP (2) | EP2313106B1 (ja) |
| JP (3) | JP5694928B2 (ja) |
| AU (1) | AU2009270435B2 (ja) |
| CA (1) | CA2730531A1 (ja) |
| DK (2) | DK2313106T3 (ja) |
| ES (2) | ES2571956T3 (ja) |
| HR (2) | HRP20160760T1 (ja) |
| HU (2) | HUE027953T2 (ja) |
| PL (2) | PL2313106T3 (ja) |
| PT (1) | PT2638915T (ja) |
| WO (1) | WO2010006809A2 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7932365B2 (en) | 2003-11-08 | 2011-04-26 | Pro Thera Biologics, Llc | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| AU2008214837B2 (en) | 2007-02-12 | 2013-01-10 | A1M Pharma Ab | Diagnosis and treatment of preeclampsia |
| AU2009260822B2 (en) | 2008-05-28 | 2016-09-22 | Prothera Biologics, Inc. | Preparation and composition of Inter-alpha inhibitor proteins from blood |
| CA2881321A1 (en) * | 2012-09-05 | 2014-03-13 | A1M Pharma Ab | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases |
| CA2885604A1 (en) * | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of ischemia using inter-alpha inhibitor proteins |
| WO2015095553A1 (en) | 2013-12-20 | 2015-06-25 | Nephrogenesis, Llc | Methods and apparatus for kidney dialysis |
| EA039776B1 (ru) | 2016-03-18 | 2022-03-11 | Гард Терапьютикс Интернэшнл Айби | Новые белки, полученные из альфа-1-микроглобулина, и их применение |
| US20190314449A1 (en) * | 2016-11-16 | 2019-10-17 | The Board Of Regents Of The University Of Texas System | Cyclic dipeptides and wound healing |
| CA3081416A1 (en) | 2017-11-03 | 2019-05-09 | Guard Therapeutics International AB | Use of alpha-1-microglobulin for protection of bone marrow cells |
| JP6906807B2 (ja) | 2018-08-31 | 2021-07-21 | 一般社団法人クラインシュタイン医工学パースペクティブ | 透析装置 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166133A (en) | 1991-04-17 | 1992-11-24 | Cetus Corporation | Method for inhibing adhesion of white blood cells to endothelial cells |
| US6103691A (en) * | 1994-03-23 | 2000-08-15 | Tschesche; Harald | Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins |
| US5910482A (en) | 1996-03-19 | 1999-06-08 | Board Of Regents, The University Of Texas System | Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor |
| JP2001348342A (ja) | 2001-04-12 | 2001-12-18 | Nippon Zoki Pharmaceut Co Ltd | 免疫調整・抗炎症剤 |
| DE10125883A1 (de) | 2001-05-28 | 2002-12-12 | Serumwerk Bernburg Ag | Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie |
| DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| US20070060512A1 (en) * | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
| AR045074A1 (es) * | 2003-07-23 | 2005-10-12 | Applied Research Systems | Uso de cd164 soluble en desordenes inflamatorios y autoinmunes |
| ITMI20032528A1 (it) * | 2003-12-19 | 2005-06-20 | Francesco Santangelo | Uso di cistina o di cisteina per la prevenzione e il |
| US20060105419A1 (en) | 2004-08-16 | 2006-05-18 | Biosite, Inc. | Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions |
| JP2007001922A (ja) | 2005-06-23 | 2007-01-11 | Asahi Kasei Pharma Kk | 透析患者における腎疾患改善剤、又は機能性食品 |
| US20070292421A1 (en) | 2005-07-28 | 2007-12-20 | Feinberg Bruce B | Method for treating preeclampsia |
| US20080133141A1 (en) | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| AU2008214837B2 (en) | 2007-02-12 | 2013-01-10 | A1M Pharma Ab | Diagnosis and treatment of preeclampsia |
-
2009
- 2009-07-17 EP EP09777272.7A patent/EP2313106B1/en active Active
- 2009-07-17 AU AU2009270435A patent/AU2009270435B2/en not_active Ceased
- 2009-07-17 ES ES09777272T patent/ES2571956T3/es active Active
- 2009-07-17 DK DK09777272.7T patent/DK2313106T3/en active
- 2009-07-17 CA CA2730531A patent/CA2730531A1/en not_active Abandoned
- 2009-07-17 EP EP13172049.2A patent/EP2638915B1/en not_active Not-in-force
- 2009-07-17 WO PCT/EP2009/005217 patent/WO2010006809A2/en active Application Filing
- 2009-07-17 HU HUE09777272A patent/HUE027953T2/en unknown
- 2009-07-17 US US13/054,188 patent/US10350268B2/en active Active
- 2009-07-17 PL PL09777272T patent/PL2313106T3/pl unknown
- 2009-07-17 PT PT131720492T patent/PT2638915T/pt unknown
- 2009-07-17 DK DK13172049.2T patent/DK2638915T3/en active
- 2009-07-17 HU HUE13172049A patent/HUE030274T2/en unknown
- 2009-07-17 JP JP2011517819A patent/JP5694928B2/ja not_active Expired - Fee Related
- 2009-07-17 ES ES13172049.2T patent/ES2614490T3/es active Active
- 2009-07-17 PL PL13172049T patent/PL2638915T3/pl unknown
-
2014
- 2014-11-21 JP JP2014236500A patent/JP6406987B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-10 JP JP2015241096A patent/JP6175478B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-29 HR HRP20160760TT patent/HRP20160760T1/hr unknown
- 2016-12-29 HR HRP20161808TT patent/HRP20161808T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505154A5 (ja) | ||
| JP2009500045A5 (ja) | ||
| HRP20161808T1 (hr) | Medicinska uporaba hvatača radikala i antioksidansa alfa-1-mikroglobulin | |
| NO20084199L (no) | Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom | |
| WO2007076522A3 (en) | Treatment of peripheral vascular disease using postpartum-derived cells | |
| JP2011225596A5 (ja) | ||
| JP2014519333A5 (ja) | ||
| WO2012142093A3 (en) | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
| WO2005001080A3 (en) | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system | |
| BR112022008641A2 (pt) | Métodos de tratamento com modulador de miosina | |
| ATE511847T1 (de) | Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes | |
| AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
| JP2017532343A5 (ja) | ||
| JP2018520208A5 (ja) | ||
| JP2011528333A5 (ja) | ||
| IN2014KN02752A (ja) | ||
| JP2011516477A5 (ja) | ||
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| WO2012096411A1 (ja) | 難治性炎症性腸疾患の予防又は治療方法 | |
| EP3984538A3 (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| EP4289476A3 (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| WO2010091051A3 (en) | Therapeutic use of specialized endothelial progenitor cells | |
| Adachi et al. | Prevention of brain infarction by postischemic administration of histidine in rats | |
| WO2009114539A3 (en) | Neuroprotective integrin-binding peptide and angiopoietin-1 treatments | |
| CO6160332A2 (es) | Agente para terapia y/o mejoramiento de coagulacion intravascular diseminada |